In another China pact, Lilly makes a deal with InnoCare worth up to $3.35B
Eli Lilly has signed up Beijing-based InnoCare to develop new medicines in a partnership that could be worth up to $3.35 billion if the products …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Source link







